English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, July 1, 2024
河套科創區攜手13家創新企業 君聖泰醫藥協助創新藥國際化發展
河套科创区携手13家创新企业 君圣泰医药助力创新药国际化发展
Friday, June 21, 2024
HighTide Therapeutics Presents Analyses of a Phase 2 T2DM Study at the ADA Scientific Sessions, Highlighting Glycemic and Cardiometabolic Benefits of Berberine Ursodeoxycholate (HTD1801)
Wednesday, June 5, 2024
君聖泰醫藥將在2024年國際肝病大會發布MASH臨床2a期研究分析結果,進一步展現熊去氧膽小檁鹼(HTD1801)的療效與安全性
君圣泰医药将在2024年国际肝病大会发布MASH临床2a期研究分析结果,进一步展现熊去氧胆小檗碱(HTD1801)的疗效与安全性
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801)
Friday, March 3, 2023
“天然分子” 的葫蘆裡,給慢病埋的什麼藥?
“天然分子” 的葫芦里,给慢病埋的什么药?
Wednesday, January 11, 2023
HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study)
君聖泰HTD1801治療非酒精性脂肪性肝炎(NASH)的臨床IIb 期研究(CENTRICITY研究)完成首例患者給藥

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575